A new 2026 study confirms perimenopause doubles your cardiovascular risk — but the researchers left out one important intervention. Here's what the evidence actually says.

If you're in perimenopause and no one has talked to you about your heart health, this is your sign to start that conversation.

A study published this month in the Journal of the American Heart Association analyzed cardiovascular health data from over 9,000 women and found that perimenopausal women were twice as likely to have poor cardiovascular health scores compared to women who were still having regular menstrual cycles. The biggest drivers? Cholesterol and blood sugar — two markers directly influenced by fluctuating estrogen levels.

Critically, the researchers confirmed this wasn't simply a function of aging. After controlling for age, perimenopause itself was independently associated with declining cardiovascular health. That distinction matters, because it means the hormonal transition — not just the passing of time — is driving the change.

What's Actually Happening in Your Body

As estrogen levels begin to fluctuate in perimenopause, a cascade of metabolic changes follows. Estrogen plays an active role in regulating insulin sensitivity, lipid metabolism, blood pressure, and body composition. When those levels become erratic, so do those systems. Cholesterol profiles shift — often with LDL rising and HDL falling. Insulin resistance increases. Blood pressure becomes harder to regulate. These changes can begin years before your last period.

The study's authors used the American Heart Association's Life's Essential 8 scoring system to measure cardiovascular health across reproductive stages. Median scores dropped from 73.3 in premenopausal women to 69.1 in perimenopausal women to 63.9 in postmenopausal women. The sharpest relative jump occurred at the perimenopausal transition — making it what the researchers called a "window of opportunity" for earlier screening and nutritional intervention.

That framing is right. But it's incomplete.

What the Study Didn't Mention

The researchers recommended earlier screening for blood pressure, cholesterol, and blood sugar, along with dietary changes such as following a DASH-style eating plan. These are sensible, evidence-based recommendations. But notably absent from their discussion was hormone replacement therapy — despite a substantial body of evidence supporting its cardiovascular benefits when initiated at the right time.

This is where the timing hypothesis becomes essential.

Multiple large studies — including the Danish Osteoporosis Prevention Study (DOPS) and re-analyses of the Women's Health Initiative — have shown that women who begin HRT during perimenopause or within ten years of menopause onset have significantly reduced rates of heart attack, heart failure, and cardiovascular death compared to those who start later or not at all. The KEEPS trial (Kronos Early Estrogen Prevention Study) similarly found that early initiation of estrogen therapy slowed the progression of atherosclerosis in recently menopausal women.

The original WHI data, which frightened a generation of women and clinicians away from HRT, was largely drawn from women who were older and further from menopause — a very different population from the perimenopausal women this new AHA study is focusing on.

The Menopause Society's current position is clear: for healthy women under 60, or within ten years of menopause onset, the cardiovascular benefits of HRT outweigh the risks.

Why This Matters for Your Care

The perimenopausal window identified in this study is the same window during which HRT has its greatest potential cardiovascular benefit. These two bodies of evidence, read together, point to the same conclusion: perimenopause is the time to act — not just with screening and dietary changes, but with a full evaluation of whether hormone therapy is appropriate for you.

That means getting your cholesterol, fasting glucose, and blood pressure checked. It also means having a frank conversation with a provider who understands both the hormonal and cardiovascular dimensions of this transition.

At The Lee Clinic, this is exactly the kind of whole-picture assessment we provide. If you're in perimenopause and want to understand what your numbers mean — and what your options are — we're here for that conversation.

Sources:

• Nayak A, Arora G, et al. Journal of the American Heart Association, May 2026
• The Menopause Society (formerly NAMS) Position Statement on HRT
• DOPS Trial — Schierbeck et al., BMJ, 2012
• KEEPS Trial — Harman et al., JAMA Internal Medicine, 2014
• WHI re-analyses — Manson JE et al.